239 related articles for article (PubMed ID: 36257534)
1. Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors.
Hooiveld-Noeken JS; Eggen AC; Rácz E; de Vries EGE; Reyners AKL; Jalving M
Crit Rev Oncol Hematol; 2022 Dec; 180():103855. PubMed ID: 36257534
[TBL] [Abstract][Full Text] [Related]
2. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
Ascierto PA; Schadendorf D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases.
Baltazar D; Zeitouni N; Patel N; Moser J
J Drugs Dermatol; 2024 Feb; 23(2):e57-e59. PubMed ID: 38306125
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.
Stonesifer CJ; Djavid AR; Grimes JM; Khaleel AE; Soliman YS; Maisel-Campbell A; Garcia-Saleem TJ; Geskin LJ; Carvajal RD
Front Oncol; 2021; 11():734354. PubMed ID: 34988009
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?
Moujaess E; Merhy R; Kattan J; Sarkis AS; Tomb R
Immunotherapy; 2021 Oct; 13(15):1293-1304. PubMed ID: 34463126
[TBL] [Abstract][Full Text] [Related]
8. Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer.
Lin A; Schmalbach CE
Curr Oncol Rep; 2023 Jul; 25(7):735-742. PubMed ID: 37010785
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.
Sarver M; Brown MC; Rhodin KE; Salama AKS; Beasley GM
Hum Vaccin Immunother; 2022 May; 18(3):1943987. PubMed ID: 34254900
[TBL] [Abstract][Full Text] [Related]
10. Where do we stand with immunotherapy for nonmelanoma skin cancers in the curative setting?
Alberti A; Gurizzan C; Baggi A; Bossi P
Curr Opin Otolaryngol Head Neck Surg; 2024 Apr; 32(2):89-95. PubMed ID: 37997885
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
[TBL] [Abstract][Full Text] [Related]
12. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
13. Evolving Role of Systemic Therapies in Non-melanoma Skin Cancer.
Conforti C; Corneli P; Harwood C; Zalaudek I
Clin Oncol (R Coll Radiol); 2019 Nov; 31(11):759-768. PubMed ID: 31522944
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes.
Shalhout SZ; Kaufman HL; Emerick KS; Miller DM
Clin Cancer Res; 2022 Jun; 28(11):2211-2220. PubMed ID: 35121622
[TBL] [Abstract][Full Text] [Related]
15. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
Front Immunol; 2021; 12():609728. PubMed ID: 34887846
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis.
Mehta NK; Li AR; Nguyen SA; Kaczmar JM; Neskey DM; Day TA
Target Oncol; 2021 Nov; 16(6):743-752. PubMed ID: 34677815
[TBL] [Abstract][Full Text] [Related]
17. Update on the Use and Treatment of Targeted Molecular Inhibitors for Locally Advanced and Metastatic Non-Melanoma Skin Cancers.
Odueyungbo M; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S49-56. PubMed ID: 26730974
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors to treat cutaneous malignancies.
Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
Wessely A; Steeb T; Leiter U; Garbe C; Berking C; Heppt MV
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291277
[TBL] [Abstract][Full Text] [Related]
20. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults.
Ferrante di Ruffano L; Dinnes J; Chuchu N; Bayliss SE; Takwoingi Y; Davenport C; Matin RN; O'Sullivan C; Roskell D; Deeks JJ; Williams HC;
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013187. PubMed ID: 30521689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]